GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » Earnings Yield %

Relypsa (Relypsa) Earnings Yield % : N/A% (As of May. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relypsa Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-05-25), the stock price of Relypsa is $31.99. Relypsa's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-5.77. Therefore, Relypsa's earnings yield of today is N/A%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Relypsa's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2016 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Relypsa Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Relypsa's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=-5.770/31.99
=N/A %

Relypsa's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.770 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


Relypsa  (NAS:RLYP) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Relypsa Earnings Yield % Related Terms

Thank you for viewing the detailed overview of Relypsa's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relypsa (Relypsa) Business Description

Traded in Other Exchanges
N/A
Address
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Executives
Ronald A. Krasnow officer: See Remarks C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball officer: Chief Financial Officer & SVP C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J director 33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl officer: SVP, Chief Technology Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland officer: SVP & Chief Commercial Officer 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley director C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi 10-26-2015